Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.31 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.31 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23153061 | 0.89 | LMNA (0.33) | LMNABLMCHRM1MAPK8MAPK9 | |
| SCHEMBL19853676 | 0.89 | LMNA (0.33) | LMNABLMCHRM1MAPK8MAPK9 | |
| SCHEMBL19854886 | 0.88 | MME (0.30) | — | |
| SCHEMBL19853736 | 0.88 | ALOX15 (0.34) | LMNA | |
| SCHEMBL19853680 | 0.87 | LMNA (0.36) | LMNABLM | |
| SCHEMBL19853719 | 0.84 | OPRK1 (0.33) | LMNASMYD3 | |
| SCHEMBL23153058 | 0.84 | OPRK1 (0.33) | LMNASMYD3 | |
| SCHEMBL19853729 | 0.82 | — | — | |
| SCHEMBL19853735 | 0.82 | GRIN2B (0.41) | LMNABLMMAPK8MAPK9MAPK10 | |
| SCHEMBL19853723 | 0.82 | JAK2 (0.37) | EPHX2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220273629-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF ANTIBODIES THAT INTERACT WITH THE NMDA RECEPTOR | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2022-09-01 | — | — | US | disclosed |
| US-20220002242-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2022-01-06 | — | — | US | disclosed |
| US-10961189-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2021-03-30 | — | — | US | disclosed |
| WO-2021021996-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF ANTIBODIES THAT INTERACT WITH THE NMDA RECEPTOR | APTINYX INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| US-20190161442-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2019-05-30 | — | — | US | disclosed |
| WO-2018026763-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161442-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | LMNA 4586/4885BLM 3585/4885CHRM1 478/4885 |
| US-10961189-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | LMNA 4586/4885BLM 3585/4885CHRM1 478/4885 |
| US-20220273629-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF ANTIBODIES THAT INTERACT WITH THE NMDA RECEPTOR | GRIN2A, GRIN2B, GRIN1 | LMNA 4206/4885BLM 4221/4885CHRM1 2627/4885 |
| US-20220002242-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | LMNA 4586/4885BLM 3585/4885CHRM1 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.